Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone maintains a Buy rating on ADMA Biologics and raises the price target from $10 to $12.
May 10, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone reaffirmed a Buy rating on ADMA Biologics and increased the price target from $10 to $12, indicating a positive outlook on the company's future performance.
The upgrade in price target by a reputable analyst like Anthony Petrone suggests a strong conviction in ADMA Biologics' future growth and operational performance. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100